12-month real-life efficacy of the Minimed 780G Advanced Closed Loop system in patients living with Type 1 diabetes: a French observational, retrospective, multicentric study.

Abstract

To evaluate the evolution of glycemic outcomes in patients living with type 1 diabetes (T1D) after one year of use of the Minimed 780G advanced hybrid closed-loop system (AHCL). We conducted an observational, retrospective, multicentric study in 20 centers in France. The primary objective was to evaluate the improvement in glycemic control after one year of use of AHCL. The primary endpoint was the variation of TIR between pre-AHCL and after one-year use of AHCL. Secondary objectives were to analyze the glycemic outcomes after 3, 6, and 12 months of AHCL use, the safety, and the long-term observance of AHCL. 220 patients were included, and 200 were analyzed for the primary endpoint. 92.7% of patients continued to use AHCL. After one year of use of AHCL, TIR was 72.5 ± 10.6% (+ 9.1 %; IC95 [7.6; 10.5] as compared to pre-AHCL initiation, p<0.001), HbA1c 7.1% ± 0.7 (-0.5% IC 95 [-0.6; -0.4]; p<0.001), TBR 2.0 % [1.0; 3.0] (0.0% [-2.0; 0.0], p<0.001), TAR 24.8% ± 10.9 (-7.3% IC 95 [-8.8; -5.7]; p<0.001). More patients achieved the glycemic treatment goals of HBA1c <7.0% (45.1% vs. 18.1%, p < 0.001) and TIR >70% (59.0% vs. 29.5% p <0.001) when compared with pre-AHCL. 5 patients experienced severe hypoglycemia events and 2 patients experienced keto-acidosis. After one year of use of AHCL, people living with T1D safely improved their glucose control and a higher proportion of them achieved optimal glycemic control.